Ansa plans to use some of the funding to expand its facility in Emeryville, CA. The company will install an upgraded version of its technology which will make its DNA manufacturing more efficient. New manufacturing platforms will also be added at the Emeryville site to expand production capacity. Read the full story.
Ansa Biotechnologies, Inc. today announced that it has closed $45.2 million and secured commitments for an additional $9.2 million as part of an oversubscribed series B financing round. View the press release.
An article in Nature features Ansa’s Chief Scientific Officer and co-founder Dan Lin-Arlow discussing the unique capabilities of enzymatic DNA synthesis. Read the full story here.
Ansa Biotechnologies, Inc., the trusted partner for DNA synthesis, today announced the launch of its 50 kb DNA synthesis early access program, providing customers with extremely long and complex DNA sequences in less than four weeks.
Join us in this webinar case study to discover ways to progress and iterate scientific work that were previously unimaginable. Get an exciting look at innovative platforms, such as the Retained Endoplasmic Cleavable Secretion (RELEASE) platform developed by Stanford’s Gao Lab.
Combining its complex DNA synthesis platform with a unique long-read sequencing and analysis approach for quality control allows Ansa to produce long, complex DNA more accurately and reliably than any other DNA synthesis vendor. View the press release.
Read this editorial in Technology Networks by Ansa CSO and co-founder Dan Lin-Arlow to learn about the factors you should consider if you are looking to switch to enzymatic synthesis.
The importance of Ansa’s technology to enable synthesis of complex DNA for advanced research is featured in this editorial from Biocompare.
Ansa Biotechnologies’ DNA synthesis technology and first product launch are featured in this story from SynbioBeta.
Ansa Biotechnologies announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments. Ansa is the only company able to synthesize complete, contiguous DNA oligonucleotides as long as 600 bp without requiring assembly, delivering products as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. View the press release.